CHEMOMAB THERAPEUTICS LTD (CMMB) Stock News
NASDAQ:CMMB - Nasdaq - US16385C1045 - ADR - Currency: USD
CMMB Latest News, Press Relases and Analysis
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
Chemomab reported new clinical data to be presented at EASL 2025 that further confirms the potential of nebokitug as a first-in-class treatment for PSC....
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
Chemomab Announces New Medical and Clinical Appointments
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chemomab Therapeutics (NASDAQ:CMMB) just reported results for the second quarte...
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
Chemomab Therapeutics just reported results for the second quarter of 2024.
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
Reported positive 48-week nebokitug data from Phase 2 PSC trial. Reduced risk for disease progression and showed improvement in key markers of fibrosis. ...
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
In 2024 reported positive nebokitug Phase 2 primary sclerosing cholangitis data and aligned on a clear, efficient path to potential FDA regulatory...
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
After End-of-Phase 2 meeting, Chemomab and FDA aligned on a clear pathway to regulatory approval—a single pivotal Phase 3 study for the treatment of PSC....
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Chemomab management is participating in the Oppenheimer Movers in Rare Disease Summit on Dec 13, 2024 at the Westin Grand Central in NYC....
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Oral presentation at AASLD highlights broad clinical activity of Chemomab’s CM-101 across multiple biomarkers and its disease-modifying potential in PSC...
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics to Present at October 2024 Investor Conferences
Chemomab will participate in the ROTH Healthcare Opportunities Conference in NYC on Oct 9 and the Maxim Healthcare Virtual Summit on Oct 16 at 9am ET....
Chemomab Therapeutics to Present at October 2024 Investor Conferences
Chemomab Therapeutics to Present at September 2024 Investor Conferences
Chemomab will be presenting at the HC Wainwright Global Investment Conference and the HBM Biopharma Summit in September...
Chemomab Therapeutics to Present at September 2024 Investor Conferences
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Ph 2 PSC data showed safety/activity supporting advancing CM-101 to Ph 3. New financing extends cash runway to early 2026. 2 milestones on track for 1Q25....
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
Chemomab will report its second quarter 2024 financial results and provide a business update on August 21, 2024 at 7:00am ET....
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026...
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Chemomab has regained full compliance with the Nasdaq minimum bid price rule...
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement